1	Usability and acceptability of oral fluid- and blood-based
2	hepatitis C virus self-testing among the general population
3	and men who have sex with men in Malaysia
4	
5	Huan-Keat Chan ¹ , Xiaohui Sem ² , Elena Ivanova ^{2*} , Sheela Bai A/P Pannir Selvam ³ , Narul Aida Salleh ⁴ , Abdul
6	Hafiz Bin Mohamad Gani ⁵ , Emmanuel Fajardo ² , Sonjelle Shilton ² and Muhammad Radzi Abu Hassan ¹
7	
8	¹ Clinical Research Centre, Hospital Sultanah Bahiyah, Alor Setar, Malaysia
9	² FIND, Geneva, Switzerland
10	³ Cheras Health Clinic, Kuala Lumpur, Malaysia
11	⁴ Kuala Lumpur Health Clinic, Kuala Lumpur, Malaysia
12	⁵ Mahmoodiah Health Clinic, Johor Bharu, Malaysia
13	
14	*Corresponding Author:
15	Email: <u>elena.ivanova@finddx.org</u> (EI)
16	

17 Abstract:

Hepatitis C self-testing (HCVST) is emerging as an additional strategy that could help to expand access to HCV testing. We conducted a study to assess the usability and acceptability of two types of HCVST, oral fluid- and blood-based, among the general population and men who have sex with men (MSM) in Malaysia.

An observational study was conducted in three primary care centres in Malaysia. Participants who were layman users performed the oral fluid- and blood-based HCVST sequentially. Usability was assessed by calculating the rate of errors observed, the rate of difficulties faced by participants as well as interreader (self-test interpreted by self-tester vs interpreted by trained user) and inter-operator concordances (self-test vs test performed by trained user). The acceptability of HCV self-testing was assessed using an interviewer-administered semi-structured questionnaire. Participants were also required to read contrived test results which included "positive", "negative", and "invalid".

29 There was a total of 200 participants (100 general population, 100 MSM; mean age 33.6 ± 14.0 30 years). We found a high acceptability of oral fluid- and blood-based HCVST across both general population 31 and MSM. User errors, related to timekeeping and reading within stipulated time, were common. 32 However, the majority of the participants were still able to obtain and interpret results correctly, including that of contrived results. The high acceptability of HCVST among the participants did not appreciably 33 34 change after they had experienced both tests, with 97.0% of all participants indicating they would be 35 willing to use HCVST again and 98.5% of them indicating they would recommend it to people they knew. 36 There was no significant difference between the general population and MSM in these aspects.

Our study demonstrates that both oral fluid- and blood-based HCVST are highly acceptable among
both the general population and MSM. Both populations also showed comparable ability to conduct the

- tests and interpret the results. Overall, this study suggests that HCVST could be introduced as an addition to existing HCV testing services in Malaysia. Further studies are needed to establish the optimal positioning of self-testing alongside facility-based testing to expand access to HCV diagnosis in the country.
- 43
- 44 Keywords: HCV, self-testing, MSM, general population, usability, acceptability

45 Introduction

46	Hepatitis C virus (HCV) infection remains a major contributor to life-threatening liver
47	diseases worldwide. Approximately 58 million individuals are currently living with hepatitis C [1,
48	2]. The advent of highly effective direct-acting antivirals (DAAs), coupled with the World Health
49	Organization's (WHO) goal to eliminate HCV as a public health threat by 2030 [3], has prompted
50	global screening and treatment scale-up efforts.
51	Although 9.4 million HCV-infected individuals benefited from simplified testing
52	procedures and received DAA-based treatment between 2016 and 2021 [4], the suboptimal
53	uptake of facility-based testing, largely due to the poor accessibility of primary care, concerns
54	around stigma, and competing priorities [5, 6], has limited the expansion of treatment. Adopting
55	cost-effective yet user-friendly innovations, particularly self-testing, may help overcome such
56	challenges and make decentralized HCV testing a success [7].
57	Self-testing is a process in which an individual collects a specimen, performs a test and
58	interprets the results on their own [8, 9]. HIV self-testing (HIVST) has been used to complement
59	conventional facility-based HIV testing services [10]. It has been shown to substantially enhance
60	HIV testing uptake, especially among men who have sex with men (MSM) [11, 12]. Given the
61	overlapping risk factors and challenges of HCV and HIV, policy and programme synergies in
62	national responses to these infections have been advocated [13]. Recently, WHO issued a new
63	recommendation to use HCV self-testing (HCVST) as an additional approach to supplement
64	facility-based testing services [14]. It is critical that countries introducing HCVST into their testing

policies adapt the WHO's recommendations accordingly to the national and local context and
 most importantly, solicit community preferences.

Malaysia, an upper middle-income country with a population of 32.7 million, has an anti-HCV prevalence of approximately 1.9% in the general population [15] and 4.6% in MSM [16]. The national response to HCV in Malaysia is mainly driven by the Ministry of Health (MOH), based on principles of improving treatment accessibility and resource optimization. Despite initial successes in the expansion of DAA-based treatment [17, 18], a large majority of those infected remain undiagnosed and the MOH continues to collaborate with FIND to explore options increasing access to HCV screening.

74 Recent studies of oral fluid-based HCVST conducted in Egypt, Vietnam and Georgia have shown overall high usability and acceptability [19-21], while blood-based HCVST was shown to 75 have high usability in South Africa (in the general population) [22]. HCV self-testing would also 76 be accepted by the general population in Rwanda and people who inject drugs (PWID) in 77 Kyrgyzstan who had no actual experience of self-testing [23,24]. In this study, we made the first 78 attempt to determine the usability and acceptability of both oral fluid- and blood-based HCVST 79 among the general population and MSM in Malaysia, including understanding how well 80 participants can interpret HCVST and contrived results. 81

82

83 Methods

84 Study design and setting

This cross-sectional study was undertaken in three public primary care centres located in the State of Johor (Mahmoodiah Health Clinic) and the Federal Territory of Kuala Lumpur (Cheras Health Clinic and Kuala Lumpur Health Clinic). Apart from providing general medical care, these three centres also run special clinics for sexually transmitted diseases (STDs), where approximately 70% of patients are MSM. This study (protocol number: NMRR-20-1794-56098) was approved by the Medical Research Ethics Committee of the MOH.

91

92 Study participants and sample size

Participants were recruited via convenience sampling during a 2-month period (18 December 2020 to 21 February 2021). They were all adults (≥18 years of age) who either selfreferred to participate in this study or were receiving care at one of the three study sites at the time of being approached. All participants were considered to have an unknown HCV status as they either have never been tested for HCV before or tested negative more than 6 months prior to study enrollment. They also had no experience with either HIVST or HCVST.

Based on expert opinion derived from experience with HIVST and the finding of a recent
study comparing PWID and MSM when performing HCVST [19], this study was powered to detect
a 20% difference in the usability of HCVST between the general population and MSM (70% versus
50%). The level of significance (α) and power (1-β) was fixed at 5% and 80%, and the minimum
sample sizes required for the general population and MSM were therefore 94 individuals each.
Assuming a 5% attrition rate, a sample-size target of 100 participants per group was set.

105 HCV self-testing kits

All participants performed HCVST with two kits: OraQuick® (oral fluid-based test kit; 106 manufactured by OraSure Technologies, United States of America) and First Response[®] (blood-107 based test kit; manufactured by Premier Medical Corporation, India). OraQuick[®] (sensitivity: 108 109 98.1%; specificity: 99.6%) was already prequalified by the WHO for professional use at the time of this study, whereas First Response[®] (sensitivity: 100%; specificity: 100%) was still under the 110 review of the WHO for professional use. Both kits were repackaged and adapted for HCVST by 111 the manufacturers and labelled "for research use only". Instructions for use (IFU) in both Bahasa 112 Malaysia and English were also included in the package. No results from either test were used to 113 guide any clinical decisions. All participants received a standard HCV test at the end of the study 114 115 and were linked to treatment if necessary.

116

117 Study procedures

At the study sites, individuals were briefed about the study and screened for eligibility. After providing written consent, study procedures were carried out in a private room. A structured questionnaire was used to record their demographic data, past exposure to HCV risk factors, experience with HCV and HIV testing, and willingness to use HCVST. Participants were then provided with both written (in Bahasa Malaysia or English) and pictorial instructions about HCVST.

To reduce usability bias, half of the participants at each study site performed the oral 124 125 fluid-based test first, while the remainder used the blood-based test first. Participants were advised to avoid consuming food or using oral care products for 15 and 30 minutes, respectively, 126 127 before performing the oral fluid-based test. For the oral fluid-based test, participants swabbed 128 their upper and lower gums with the test device, placed it in the provided tube, and read the results within 20 to 40 minutes of taking the test. For the blood-based test, participants collected 129 a drop of blood by pricking a finger with a lancet, transferred the blood onto the test device, 130 131 added the diluent, and read the results after 15 minutes. Any errors observed during self-testing 132 and result interpretation by the participant were documented by a study team member using a checklist. No assistance was provided unless requested by a participant and after at least 15 133 134 minutes of repeated efforts to conduct each testing step unassisted.

To determine inter-reader concordance, a second study team member, who was blinded 135 136 to the self-reported test results, re-read the results within the stipulated time. Subsequently, to 137 determine inter-operator concordance, a third study team member, who was blinded to both the self-reported and re-read results, performed professional-use oral fluid- and blood-based tests. 138 Next, participants were required to read contrived test results which included a mix of "positive", 139 "negative", and "invalid" results (S1 Fig). Finally, a structured interview was conducted to explore 140 the acceptability of HCVST among participants, as well as to collect additional information 141 142 regarding their awareness of HCV and its treatment.

143 **Data assessment and analysis**

The usability of HCVST was expressed as the proportions of participants who were 144 145 observed to make mistakes, incorrectly interpret results, experience difficulties or require assistance when performing the tests. The inter-reader and inter-operator concordances of result 146 147 interpretation represented the degrees (in percentages) to which the test results reported by the 148 participants agreed with those re-read and found in the repeated tests, respectively. The Gwet's AC1 coefficient was also used to measure the inter-reader and inter-operator reliability of result 149 150 interpretation, given the imbalanced distribution of HCV test results across categories [25]. 151 Acceptability of HCVST among the participants, along with their awareness of hepatitis C and its 152 treatment, were summarized as numbers and percentages. Pearson's chi-square or Fisher's exact test was used to explore associations between two categorical variables, while the Mann-153 Whitney U test was used to compare means between two groups of participants. Statistical 154 analyses were performed using SPSS Statistics V21.0 (IBM, New York), with the level of 155 156 significance set at *p*<0.05.

157

158 **Results**

159 **Recruitment and characteristics of participants**

Of 221 individuals approached, 216 (97.7%) fulfilled the eligibility criteria and 200 (92.6%) consented to participate in this study. The number of participants recruited in the three study sites was 60 (30.0%), 66 (33.0%) and 74 (37.0%) respectively. All participants completed both oral fluid- and blood-based HCVST, as well as the post-testing interviews (Fig 1).

Fig 1. Flowchart of participant enrolment. GP, general population; HCVST, hepatitis C selftesting; MSM, men who have sex with men.

166 Table 1 shows the participants' self-reported characteristics; their mean age was $33.6 \pm$ 167 14.0 years; most were male (75.0%) and unmarried (65.0%). MSM were more likely to make >1 visit to clinics annually compared with the general population (80.0% vs. 39.0%, p < 0.001). 168 Majority of the MSM participants have been previously tested for HIV (96.0% vs 50%, p < 0.001); 169 59% of them reported a positive HIV test result. Although none of the participants had prior 170 171 experience with HIV or HCV self-testing, participants from the general population had more 172 experience with performing home-based testing such as pregnancy, glucose monitoring and blood pressure tests (43.0% vs. 16%; p < 0.001). Before taking the self-test, 83.0% of the 173 participants across both population groups were aware of self-testing approaches in general and 174 175 almost all the participants (98.0%) expressed their willingness to use HCVST if it was available.

177 **Table 1:** Self-reported characteristics of participants: overall, general population and men who

have sex with men.

Characteristics	Overall (n = 200)		Subgroup	
		GP	MSM	<i>p</i> -value
		(n = 100)	(n = 100)	-
Age, median (IQR)	33.6 (14.0)	35.8 (19.0)	29.5 (11.0)	0.121 ^a
Sex, n (%)				
Male	157 (78.5)	57 (57.0)	100 (100.0)	-
Female	43 (21.5)	43 (43.0)	_	
Education level, n (%)				
Tertiary	104 (52.0)	45 (45.0)	59 (59.0)	0.123 ^b
Secondary/post-secondary	90 (45.0)	51 (51.0)	39 (39.0)	
No formal education/primary	6 (0.3)	4 (4.0)	2 (2.0)	
Work status, n (%)				
Employed/self-employed	163 (81.5)	75 (75.0)	88 (88.0)	0.018 ^c
Unemployed	37 (18.5)	25 (25.0)	12 (12.0)	
Marital status, n (%)				
Unmarried	130 (65.0)	39 (39.0)	91 (91.0)	<0.001 b
Married or living with a partner	61 (30.5)	54 (54.0)	7 (7.0)	
Divorced, separated or widowed	9 (4.5)	7 (7.0)	2 (2.0)	
History of exposure to HCV risk factors, n (%)				
Condomless anal intercourse	80 (40.0)	-	80 (80.0)	-
Dental procedure	72 (36.0)	42 (42.0)	30 (30.0)	0.077 ^c
Surgical procedure	38 (19.0)	23 (23.0)	15 (15.0)	0.149 ^c
Sharing shaving tool or toothbrush	14 (7.0)	5 (5.0)	9 (9.0)	0.268 ^c
Having a tattoo	4 (2.0)	1 (1.0)	3 (3.0)	0.621 ^b
Injecting non-prescription drugs	2 (1.0)	0 (0.0)	2 (2.0)	0.497 ^b
Frequency of clinic visit, n (%)				
>1 time per year	119 (59.5)	39 (39.0)	80 (80.0)	<0.001 b
1 time per year	42 (21.0)	27 (27.0)	15 (15.0)	
Rarely	33 (16.5)	29 (29.0)	4 (4.0)	
Never	6 (3.0)	5 (5.0)	1 (1.0)	
Latest HCV test result, n (%)				
Negative	42 (21.0)	9 (9.0)	33 (33.0)	< 0.001 ^c
Never tested	158 (79.0)	91 (91.0)	67 (67.0)	
Latest HIV test result, n (%)				
Positive	60 (30.0)	1 (1.0)	59 (59.0)	<0.001 ^b
Negative	86 (43.0)	49 (49.0)	37 (37.0)	
Never tested	54 (27.0)	50 (50.0)	4 (4.0)	
Aware that at least one type of home-based self-	166 (83.0)	87 (87.0)	79 (79.0)	0.132 ^c
testing approach is available, n (%)				
Has experience with performing any home-based	59 (29.5)	43 (43.0)	16 (16.0)	< 0.001 ^c
self-testing, n (%)				
Willing to use home-based HCV self-testing if it is	196 (98.0)	98 (98.0)	98 (98.0)	>0.95 b
made available ^d				

179 HCV, hepatitis C virus; GP, general population; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who

have sex with men.

^a Mann–Whitney U test; ^b Fisher's exact test; ^c Pearson's chi-square test; ^d Asked before performing HCVST.

183 Usability of HCVST

For the oral fluid-based HCVST, 53.0% of the participants completed the self-test 184 procedure without any error. The most common mistakes observed during the pre-testing steps 185 were not practicing proper timekeeping (24.5%) and not reading the test results within the 186 187 stipulated time (38.5%). Excluding these two mistakes, 87.5% of the participants completed the 188 self-test procedure without any error. In addition, 88.5% of the participants completed the selftest procedure without any difficulty and 95.5% completed the self-test procedure without any 189 assistance. The general population and MSM did not differ in any of the above aspects of oral 190 fluid-based HCVST (Table 2). In terms of the blood-based HCVST, 28.0% of the participants 191 completed the self-test procedure without any error. The most common mistakes observed 192 193 during the pre-testing steps were not washing hands in warm water and drying them before 194 performing the test (58.0%); not waiting long enough (15 minutes after adding the diluent) to 195 read the test results (44.0%); not choosing a middle or ring finger to prick for the test (43.5%); not practicing correct timekeeping (35.0%); not discarding the first drop and using the second 196 drop of blood for the test (22.0%); and not massaging and warming the finger before the test 197 (20.0%). Despite these errors, 62.5% of the participants completed the self-test procedure 198 199 without any difficulty and 87.5% completed the self-test procedure without any assistance. 200 Compared with the general population, MSM were less likely to experience difficulties (6.0% vs. 16.0%; p = 0.024) and make errors (1.0% vs. 11.0%; p = 0.003) when pricking their fingers with a 201 lancet (Table 3). 202

204 Table 2: Assessment of mistakes, difficulties and assistance required in oral fluid-based self-

testing: overall, general population and men who have sex with men.

Step	Overall (n	Subgroup		
	= 200)	GP	MSM	<i>p</i> -value
		(n = 100)	(n = 100)	
No. of participants who made errors in pre-testing steps, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Reading and using the instructions for use	0 (0.0)	0 (0.0)	0 (0.0)	-
Removing the test tube from the test pack	0 (0.0)	0 (0.0)	0 (0.0)	-
Removing the cap from the test tube	0 (0.0)	0 (0.0)	0 (0.0)	-
Placing the tube into the stand	3 (1.5)	0 (0.0)	3 (3.0)	0.246 ^a
Removing the test device from the test pack	0 (0.0)	0 (0.0)	0 (0.0)	-
No. of participants who made errors in testing steps, n (%)				
Avoidance of touching the flat pad	12 (6.0)	7 (7.0)	5 (5.0)	0.522 ^b
Collecting oral fluid	14 (7.0)	4 (4.0)	10 (10.0)	0.096 ^b
Placing of test device in the tube	2 (1.0)	0 (0.0)	2 (2.0)	0.497 ^a
Timekeeping	49 (24.5)	28 (28.0)	21 (21.0)	0.250 ^b
Reading results within 20-40 minutes after the test	77 (38.5)	41 (41.0)	36 (36.0)	0.467 ^b
No. of participants who made at least one error, n (%)	94 (47.0)	47 (47.0)	47 (47.0)	>0.95 ^b
No. of participants who made at least one error (excluding those	25 (12.5)	11 (11.0)	14 (14.0)	0.521 ^b
related to timekeeping and reading results within stipulated				
time), n (%)				
No. of participants with the following observed difficulty, n (%)				
Opening the package	2 (1.0)	2 (2.0)	0 (0.0)	0.497 ^a
Opening the test tube	5 (2.5)	5 (5.0)	0 (0.0)	0.059 ^a
Sliding the tube into the stand	13 (6.5)	4 (4.0)	9 (9.0)	0.152 ^b
Placing the test device into the tube	2 (1.0)	0 (0.0)	2 (2.0)	0.497 ^a
Reading and interpreting the results	3 (1.5)	1 (1.0)	2 (2.0)	>0.95 ^a
No. of participants with observed difficulties for at least one step,	23 (11.5)	12 (12.0)	11 (11.0)	0.825 ^b
n (%)				
No. of participants requiring assistance, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Opening the test tube	2 (1.0)	1 (1.0)	1 (1.0)	>0.95 ^a
Sliding the tube into the stand	7 (3.5)	2 (2.0)	5 (5.0)	0.445 ^a
Placing the test device into the tube	1 (0.5)	0 (0.0)	1 (1.0)	>0.95 ^a
Reading the results	0 (0.0)	0 (0.0)	0 (0.0)	-
No. of participants requiring assistance for at least one step, n	9 (4.5)	3 (3.0)	6 (6.0)	0.498 ^a
(%)				

206 GP, general population; MSM, men who have sex with men.

^a Fisher's exact test;

^b Pearson's chi-square test

Table 3: Assessment of mistakes, difficulties and assistance required in blood-based self-testing:

overall, general population and men who have sex with men.

Step	Overall (n = 200)		Subgroup	
		GP (n = 100)	MSM (n = 100)	p-value
No. of participants who made errors in pre-testing steps, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Reading and using the instructions for use	1 (0.5)	0 (0.0)	1 (1.0)	>0.95 ª
Removing the test device from the foil pouch	0 (0.0)	0 (0.0)	0 (0.0)	-
Washing hands in warm water and drying them	116 (58.0)	61 (61.0)	55 (55.0)	0.390 ^b
Choosing a middle or ring finger	87 (43.5)	43 (43.0)	44 (44.0)	0.887 ^b
Massaging and warming the finger	40 (20.0)	20 (20.0)	20 (20.0)	>0.95 ^b
Cleaning fingertip with alcohol pad	3 (1.5)	2 (2.0)	1 (1.0)	>0.95 °
No. of participants who made errors in testing steps, n (%)				
Pressing the lancet against the finger to prick skin	12 (6.0)	11 (11.0)	1 (1.0)	0.003 b
Wiping away the first drop of blood and rubbing to create a second	44 (22.0)	23 (23.0)	21 (21.0)	0.733 ^b
Using the transfer device to collect the drop of blood	8 (8.0)	3 (3.0)	5 (5.0)	0.721 ^a
Dispensing the whole blood into the round specimen well	2 (1.0)	2 (2.0)	0 (0.0)	0.497 ^a
Applying the plaster	25 (12.5)	11 (11.0)	14 (14.0)	0.521 ^b
Twisting and pulling the cap to open assay diluent, then dispensing	14 (7.0)	4 (4.0)	10 (10.0)	0.096 ^b
two drops of the assay diluent into the specimen well				
Timekeeping	70 (35.0)	38 (38.0)	32 (32.0)	0.374 ^b
Reading the results 15 minutes after adding the diluent	88 (44.0)	47 (47.0)	41 (41.0)	0.393 ^b
No. of participants who made at least one error, n (%)	144 (72.0)	74 (74.0)	70 (70.0)	0.529 ^b
No. of participants who made at least one error (excluding	145 (72.5)	74 (74.0)	71 (71.0)	0.635 ^b
timekeeping and reading results within stipulated time), n (%)				
No. of participants with the following observed difficulty, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Pricking a finger	22 (11.0)	16 (16.0)	6 (6.0)	0.024 ^b
Obtaining a blood drop	23 (11.5)	13 (13.0)	10 (10.0)	0.506 ^b
Collecting the blood drop with the transfer device	54 (27.0)	26 (26.0)	28 (28.0)	0.750 ^b
Dispensing the diluent on the specimen well	5 (2.5)	3 (3.0)	2 (2.0)	>0.95 ª
Reading the results	1 (0.5)	1 (1.0)	0 (0.0)	>0.95 ª
No. of participants with observed difficulties for at least one step,	75 (37.5)	41 (41.0)	34 (34.0)	0.307 ^b
n (%)				
No. of participants requiring assistance, n (%)				
Opening the package	0 (0.0)	0 (0.0)	0 (0.0)	-
Obtaining a blood drop	1 (0.5)	1 (1.0)	0 (0.0)	>0.95 ª
Transferring the blood drop to the device	10 (5.0)	5 (5.0)	5 (5.0)	>0.95 ^b
Dispensing the diluent onto the sample well	4 (2.0)	1 (1.0)	3 (3.0)	0.621 ^a
Reading the results	0 (0.0)	0 (0.0)	0 (0.0)	-
No. of participants requiring assistance for at least one step, n (%)	25 (12.5)	15 (15.0)	10 (10.0)	0.285 ^b

213 GP, general population; MSM, men who have sex with men.

^a Fisher's exact test;

^b Pearson's chi-square test

216

218 HCVST result interpretation

219	In this study, no positive result was detected by trained study staff re-reading the self-
220	test nor by trained study stuff administering a professional test. For both the oral fluid-based and
221	blood-based HCVST, there were high inter-reader concordances among the general population
222	and MSM groups at 97.0% vs 99.0% and 99.0% vs 98.0% respectively (Table 4). The Gwet's AC1
223	coefficients were 0.76 and 0.98 for the oral fluid-based HCVST among the general population and
224	MSM, respectively, while they were 0.98 and 0.60 for the blood-based HCVST among the general
225	population and MSM, respectively. Inconsistent result interpretation between readers was
226	documented in four cases of oral fluid-based testing (three participants from the general
227	population read their negative results as positive or invalid, while one MSM read their invalid
228	result as negative) and in three cases of blood-based testing (one participant from the general
229	population read their invalid result as negative, while two MSM read their negative results as
230	positive or invalid).

Table 4: Assessment of inter-reader and inter-operator agreement in test result interpretation.

Participant interpretation Inter-reader concordance			Inter-operator concordance					
	(re-read by trained staff)			(re	e-tested by tr	ained staff)	1	
	Positive	Negative	Invalid	Total	Positive	Negative	Invalid	Total
Oral fluid-based test in GP (n =	: 100)							
Positive	0	1	0	1	0	1	0	1
Negative	0	90	0	90	0	90	0	90
Invalid	0	2	7	9	0	8	1	9
Total	0	93	7	100	0	99	1	100
Invalid rate (%)		7.0				1.0		
Concordance (%)		97.0)			91.0)	
Gwet's AC1 coefficient		0.76	5			0.89)	
Oral fluid-based test in MSM (n = 100)							
Positive	0	0	0	0	0	0	0	0
Negative	0	97	1	98	0	98	0	98
Invalid	0	0	2	2	0	2	0	2
Total	0	97	3	100	0	100	0	100
Invalid rate (%)		3.0				0.0		
Concordance (%)		99.0)			98.0)	
Gwet's AC1 coefficient		0.98	3			0.99)	
Blood-based test in GP (n = 10	0)							
Positive	0	0	0	0	0	0	0	0
Negative	0	96	1	97	0	97	0	97
Invalid	0	0	3	3	0	3	0	3
Total	0	96	4	100	0	100	0	100
Invalid rate (%)		4.0				0.0		
Concordance (%)		99.0)			97.0)	
Gwet's AC1 coefficient		0.98	3			0.99		
Blood-based test in MSM (n =	100)							
Positive	0	1	0	1	0	1	0	1
Negative	0	96	0	96	0	96	0	96
Invalid	0	1	2	3	0	3	0	3
Total	0	98	2	100	0	100	0	100
Invalid rate (%)		2.0				0.0		
Concordance (%)		98.0)			96.0)	
Gwet's AC1 coefficient		0.60)			0.99		

233 GP, general population; MSM, men who have sex with men.

The inter-operator concordances for the oral fluid-based HCVST were 91.0% and 98.0% 235 236 among the general population and MSM, respectively; for the blood-based HCVST, the interoperator concordances were 97.0% and 96.0% among the general population and MSM, 237 respectively. The Gwet's AC1 coefficients were 0.89 and 0.99 for the oral fluid-based HCVST 238 239 among the general population and MSM, respectively, while they were 0.99 and 0.99 for the blood-based HCVST among the general population and MSM, respectively. The results obtained 240 from the professional-use tests conducted by trained users were different from those reported 241 242 by the participants in eleven and seven cases of oral fluid- and blood-based tests, respectively. 243 Among the eleven discordant cases involving oral fluid-based HCVST, one participant in the general population who interpreted their result as positive, was negative when retested by a 244 trained user, while eight and two participants among the general population and MSM, 245 respectively and who interpreted their results as invalid, were all negative on retesting. Among 246 247 the seven discordant cases involving blood-based HCVST, one MSM participant, who interpreted their result as positive, was negative when retested by a trained user, while three participants in 248 249 each of the general population and MSM groups and who interpreted their results as invalid, were all negative on retesting. 250

Participants were generally able to read positive, negative, and invalid contrived results for both the oral fluid- and blood-based tests (Table 5). Accuracy of result interpretation was similar across both study populations and types of HCVST. Overall, majority of the contrived test results were interpreted correctly. Positive results with a clear test line and negative results were most accurately interpreted by the participants with over 97% of correct interpretations. Weak positives with faint test line and invalid results with test line only posed some difficulties for

interpretation. Contrived oral fluid HCVST devices displaying invalid test line-only results were
read correctly by 62.5% of the participants, while similar blood-based HCVST devices were read
correctly by 78.5% of the participants. Weak positive results with a clear control and a faint test
line were least accurately interpreted by the participants (51.3% for blood-based HCVST and 64%
for oral fluid-based HCVST).

Table 5: Assessment of accuracy in the interpretation of test results based on contrived tests.

Test result			Co	rrect interp	retation, n (%)			
	Oral fluid-based test				Blood-based test			
	Overall	GP	MSM	<i>p</i> -value	e Overall GP		MSM	<i>p</i> -value
	(n = 200)	(n = 100)	(n = 100)		(n = 200)	(n = 100)	(n = 100)	
Positive	196 (98.0)	98 (98.0)	98 (98.0)	>0.95 ^a	193 (97.5)	98 (98.0)	97 (97.0)	>0.95 ^a
(with clear								
control and test								
lines)								
Weak positive	128 (64.0)	60 (60.0)	68 (68.0)	0.239 ^b	103 (51.3)	50 (50.0)	53 (53.0)	0.671 ^b
(with a clear								
control line and a								
faint test line)								
Negative	194 (97.0)	97 (97.0)	97 (97.0)	>0.95 ^a	195 (97.5)	98 (98.0)	97 (97.0)	>0.95 ^a
(with only a clear								
control line)								
Invalid	191 (95.5)	96 (96.0)	95 (95.0)	>0.95 ^a	192 (96.0)	97 (97.0)	95 (95.0)	0.721 ^a
(without either								
control or test								
lines)								
Invalid	125 (62.5)	63 (63.0)	62 (62.0)	0.884 ^b	157 (78.5)	81 (81.0)	76 (76.0)	0.389 ^b
(with only a clear								
test line)								
TOTAL	834 (83.4)	414 (82.8)	420 (84.0)	0.610 ^b	840 (84.0)	424 (84.8)	418 (83.6)	0.603 ^b

263 GP, general population; MSM, men who have sex with men.

a Fisher's exact test;

^b Pearson's chi-square test.

266 Acceptability of HCVST

267	The acceptability of HCVST among the participants did not appreciably change after they
268	had experienced both types of tests (Table 6). Although more than half (52.5%) of all participants
269	were unaware of hepatitis C treatment and its availability in their communities, 97.0% of them
270	expressed their willingness to use HCVST again and 98.5% would recommend it to their family
271	and friends. The participants also expressed a preference to perform HCV self-testing in a primary
272	care centre (33.5%), by themselves at home (20.0%), or by health staff in a primary care centre
273	(20.0%). Just over half (51.5%) of all participants preferred oral fluid- over blood-based HCVST.
274	The main reasons given for preferring the oral fluid-based test, as captured by an open-ended
275	question, were its pain-free nature and ease of use. Nevertheless, 22.5% of participants did not
276	express a preference. The two groups of participants did not differ in their views of HCVST, except
277	that MSM were less willing to take the test kits home to their family and friends (76.0% vs. 88.0%;
278	p = 0.045). The main reasons MSM gave for being unwilling to bring the test kits home to their
279	family and friends, as captured by an open-ended question, were a lack of knowledge and
280	confidence to explain the tests.

282 **Table 6**: Acceptability of HCVST and additional information regarding awareness of HCV and its

283 treatment.

Aspect	Overall (n =		Subgroup	
	200)	GP	MSM (n =	<i>p</i> -value
		(n = 100)	100)	
Willing to use HCVST again, n (%)	194 (97.0)	98 (98.0)	96 (96.0)	0.407 ^a
Willing to recommend the test to family and friends, n (%)	197 (98.5)	99 (99.0)	98 (98.0)	>0.95 ^b
Willing to take the test kits to family and friends, n (%)	164 (82.0)	88 (88.0)	76 (76.0) ^c	0.045 ^a
Preferred HCV testing approach, n (%)				
By oneself in a primary care centre	67 (33.5)	29 (29.0)	38 (38.0)	0.532 ^a
By oneself at home	40 (20.0)	24 (24.0)	16 (16.0)	
By health staff in a primary care centre	40 (20.0)	20 (20.0)	20 (20.0)	
During a regular check-up in a health facility	14 (7.0)	6 (6.0)	8 (8.0)	
During a screening campaign	4 (2.0)	3 (3.0)	1 (1.0)	
No specific preference	35 (35.0)	18 (18.0)	17 (17.0)	
Preferred HCVST type, n (%)				
Oral fluid-based	103 (51.5) ^d	59 (59.0)	44 (44.0)	0.097 ^a
Blood-based	52 (26.0)	21 (21.0)	31 (31.0)	
No specific preference	45 (22.5)	20 (20.0)	25 (25.0)	
Will contact the health facility if HCVST result is positive, n (%)	163 (81.5)	82 (82.0)	81 (81.0)	0.856 ^a
Will take a confirmatory test if HCVST result is positive, n (%)	68 (34.0)	28 (28.0)	40 (40.0)	0.073 ^a
Awareness about hepatitis C treatment, n (%)				
Aware that there is treatment and cure	71 (35.5)	32 (32.0)	39 (39.0)	0.561 ^a
Aware that there is treatment but unsure of cure	24 (12.0)	12 (12.0)	12 (12.0)	
Unaware that there is treatment and cure	105 (52.5)	56 (56.0)	49 (49.0)	
Awareness about availability of hepatitis C treatment in one's				
community, n (%)				
Available	122 (61.0)	62 (62.0)	60 (60.0)	0.616 ^b
Available but not nearby	6 (3.0)	4 (4.0)	2 (2.0)	
Not available or not sure	72 (36.0)	34 (34.0)	38 (38.0)	

284 GP, general population; HCVST, hepatitis C virus self-testing; MSM, men who have sex with men.

^a Pearson's chi-square test;

286 ^b Fisher's exact test;

287 ^c Main reasons for the unwillingness among MSM to bring the test kits to their family and friends, as captured in an open-ended

288 question, were a lack of knowledge and confidence to explain the tests;

^d Main reasons for preferring the oral fluid-based test, as captured in an open-ended question, were its pain-free nature and ease

290 of use.

292 **Discussion**

293 To the best of our knowledge, this study is the first one to report the usability and acceptability of oral fluid- and blood-based HCVST in two populations in a country. By targeting 294 both the general population and MSM, this study has also provided insights into the usability of 295 HCVST among individuals at different levels of risk for HCV infection in Malaysia. The world is 296 297 currently witnessing an expanding epidemic of sexually transmitted HCV among MSM [26, 27]; this study demonstrates that HCVST is a highly acceptable testing modality among MSM in a 298 299 religiously and culturally conservative society such as Malaysia and hence has a high potential to enhance screening coverage in this high-risk population. Using HCVST in addition and as a 300 complement to HCV testing services in primary care centres also represents another milestone 301 302 for Malaysia, which has a relatively low prevalence of HCV in the general population [15, 28] and is seeking to micro-eliminate HCV by targeting specific populations [17, 18, 29, 30]. 303

Our findings showed that for both HCVST types, the most common mistakes made by 304 305 participants in this study were not practicing good timekeeping and not reading the results within the stipulated time period (participants tended to read the results once the specimen moved 306 307 across the result window or once the control line appeared). These critical steps could affect the sensitivity of a HCVST, leading to invalid results or false negatives. In our study, we observed 2 308 out of the 3 invalid results reported by participants were read by them prematurely – just after 309 310 the specimen moved across the result window – and both turned to be negative when re-read by the trained study staff. We could not assess the likelihood of false negative results as we had 311 no HCV positive cases in our study population, however, reading results before stipulated time 312

could cause false negative results and should this user error persist, it could be a major issue 313 314 during scale-up of HCVST. The study was conducted before a massive roll out of rapid testing for COVID-19 and it is possible that participants in Malaysia at the time were not sensitized to the 315 316 use of rapid diagnostic tests (RDTs) and might be unaware of the importance of timekeeping 317 when using RDTs. These mistakes were not observed in Egypt or Vietnam where RDTs have been widely used for screening and diagnosis of infectious diseases [18, 19]. Henceforth the usability 318 in Malaysia might gradually improve as the population gets more familiar with the use of RDTs 319 320 for self-testing. Such mistakes could also be attributed to unclear instructions in the IFU and 321 might be prevented by further optimizing the IFU and providing supplementary material such as video instructions and flyers. The use of a smartphone application with timer function during 322 323 HCVST may also guide users to perform these critical steps accurately. While pictorial instructions 324 have shown great potential elsewhere to overcome cultural barriers in promoting self-testing 325 [31], our findings highlight the importance of improving the pictorial instructions in relation to timekeeping and reading the results within the stipulated time period before any scale-up of 326 327 HCVST. Additionally, the enrolled participants might have overlooked these two aspects as they could be in a hurry to complete the study procedures. Earlier on, they have spent some significant 328 329 time in the primary care centres for standard of care before undergoing the study procedures 330 and could have wanted to return to work or school as soon as they could. In the near future, 331 when HCVST is made available outside this study and when individuals can conduct HCVST in their home or at a preferred location, these mistakes might be significantly reduced. 332

333 Another very frequent error observed during the blood-based HCVST was skipping hand 334 washing step recommended prior to sampling. However, this error was considered less critical as

it is unlikely to lead to invalid or false results, as indicated by an invalid rate of 2.0 – 4.0% and an 335 336 inter-operator agreement of more than 96.0%. A further challenge with the blood-based HCVST was the need to obtain and transfer a blood sample, as 27.0% of all participants made mistakes 337 transferring the blood drop to the test device. With regards to additional help provided to 338 339 participants while they performed the two types of HCVST, transferring the blood drop to the test device required the highest degree of assistance (5.0%). This observation is consistent with 340 an earlier study that reported challenges with specimen collection for blood-based HIVST [32]. 341 342 Again, it is possible that errors in blood-based HCVST procedures were made as participants in Malaysia were not yet sensitized to the use of RDTs and would reduce over time. Consistent to 343 this assumption, we observed that MSM generally experienced fewer difficulties than the general 344 345 population when pricking their fingers to obtain blood, likely due to their past exposure to RDTs administered by healthcare workers or community workers for HIV or HCV. Difficulties in 346 347 obtaining blood and handling the test device could discourage new self-testers; therefore, product refinement and simplified testing procedures are necessary [33]. More guidance on 348 specimen collection, such as video-based demonstration [34], is warranted, especially if blood-349 based HCVST were to be extended to the general population. 350

351 . Consistent with findings among MSM in Vietnam and Egypt [18, 19], our study indicated 352 high inter-reader concordances and reliability in the interpretation of results for both oral fluid-353 and blood-based HCVST. Furthermore, the ability of the participants to differentiate between 354 clear "positive", "negative", and "invalid" test results was evidenced by their correct 355 interpretation of contrived test results. We observed some difficulties in interpreting weak

positive results with a faint test line indicating to a need for additional guidance on how tointerpret such results.

358 Consistent with findings from Egypt and Vietnam [19, 20], the participants expressed a 359 strong willingness to use HCVST again and to recommend it to their family and friends. They also expressed a clear preference for oral fluid- over blood-based testing, as did the general 360 population in Rwanda and PWID in Kyrgyzstan who had no actual experience of self-testing 361 [23,24]. In our study, the participants from both groups reported a preference for oral fluid-based 362 363 HCVST that can be attributed to its ease of use and pain-free nature, which were also reasons for 364 the high acceptability of oral fluid-based HIVST [11, 12]. However, it is worth noting that for 365 HIVST, studies have reported a greater preference for blood- over oral fluid-based self-tests [35, 366 36]. Only one-fifth of participants in our study preferred to perform HCVST by themselves at 367 home. This may imply that they lacked confidence to perform the test alone by themselves at the 368 time of the study, despite the written and pictorial instructions provided. A lack of knowledge and confidence to explain the self-test, as reported in responses to an open-ended question 369 administered during this study, and the possible complication of punitive laws and discrimination 370 against sexual minorities in Malaysia [37, 38], may also have contributed to the reduced 371 willingness of MSM to take the test kits to family and friends. Together, these findings justify 372 continuous efforts to optimize self-testing products, improve IFU, and establish a non-373 374 discriminatory hepatitis C care model, as recommended by the WHO [14].

The major limitation of this study lies in its focus on individuals who were willing to seek care, had access to health facilities and were enrolled based on their willingness to try HCVST. The structured questionnaires were limited in scope and could not fully capture participants'

378 perceptions of the self-testing experience and acceptability of the self-tests. The usability and 379 acceptability of HCVST among hard-to-reach populations, such as those who live in rural areas 380 and are concerned about stigma, remain unclear. Furthermore, the absence of positive HCV test 381 results among the participants limited the assessment of the inter-operator reliability of HCVST. 382 The MOH, in collaboration with the Malaysian AIDS Council and FIND, has recently

initiated another study to address these limitations, mainly through the use of a web-based platform and online distribution to reach out to more potential self-testers [39]. While selftesters with a positive HCV result are expected to present themselves for further care, the MOH also recognizes the need to enhance public awareness of hepatitis C and the availability of curative treatment in health facilities across the country.

388

389 **Conclusion**

This study demonstrated that both oral fluid- and blood-based HCVST were highly 390 acceptable among both the general population and MSM in Malaysia. The general population 391 and MSM showed comparable ability to conduct the tests and interpret the results. However, 392 393 the frequencies of making critical errors related to timekeeping and reading results within stipulated time period were very high. Overall, this study suggests that both oral fluid- and blood-394 based HCVST could be introduced as an addition to existing HCV testing services for populations 395 396 at different levels of risk for HCV infection in Malaysia, provided that sufficient guidance and 397 clearer IFU (particularly highlighting the need for proper timekeeping and reading within the 398 stipulated time) are in place.

399 Acknowledgements

400	The authors would like to thank the Government of Netherlands for the support; study
401	participants for their involvement; MOH study teams for the implementation of this study; the
402	following civil society organizations for their support in the recruitment of participants - PT
403	Foundation and Intan Life Zone Welfare Society; OraSure Technologies, United States of America,
404	and Premier Medical Corporation, India, for the in-kind contribution of research-use only HCV
405	self-test kits for this study. The authors would also like to thank Cheryl Johnson, Mohammed
406	Jamil, Niklas Luhmann and Philippa Easterbrook for their contributions in conceptualizing and
407	developing protocols for the HCVST evaluation studies; and the Director-General of Health,
408	Malaysia, for his support throughout the conduct of this study and permission to publish the
409	findings.

Editorial support, under the direction of the authors and funded by FIND, was providedby Adam Bodley.

412

413 **References**

Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. World
 Health Organization; 2021.

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus
infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333418 42.

419 3. Global Health Sector Strategy on Viral Hepatitis 2016–2021: Towards Ending Viral Hepatitis. World
420 Health Organization; 2016.

421 4. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis c virus422 infection. World Health Organization; 2018.

423 5. Guidelines on Hepatitis B and C testing. World Health Organization; 2017.

424 6. Easterbrook PJ, Group WHOGD. Who to test and how to test for chronic hepatitis C infection -

425 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65(1 Suppl):S46-S66.

426 7. Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators

427 of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct

428 J. 2014;11:1.

429 8. Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing:
430 innovations in testing technologies and approaches. BMC Infect Dis. 2017;17(Suppl 1):699.

431 9. Shehata N, Austin T, Ha S, Timmerman K. Barriers to and facilitators of hepatitis C virus screening
432 and testing: A scoping review. Can Commun Dis Rep. 2018;44(7-8):166-72.

433 10. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV
 434 infection: recommendations for a public health approach. Geneva: World Health Organization; 2016.

Jiang H, Xie Y, Xiong Y, Zhou Y, Lin K, Yan Y, et al. HIV self-testing partially filled the HIV testing gap
among men who have sex with men in China during the COVID-19 pandemic: results from an online
survey. J Int AIDS Soc. 2021;24(5):e25737.

Johnson CC, Kennedy C, Fonner V, Siegfried N, Figueroa C, Dalal S, et al. Examining the effects of
HIV self-testing compared to standard HIV testing services: a systematic review and meta-analysis. J Int
AIDS Soc. 2017;20(1):21594.

441 13. Wiktor S, Ford N, Ball A, Hirnschall G. HIV and HCV: distinct infections with important overlapping
442 challenges. J Int AIDS Soc. 2014;17:19323.

443 14. Recommendations and guidance on hepatitis C virus self-testing. Geneva: World Health
444 Organization; 2021.

15. Md Said R, Mohd Zain R, Chan HK, Soelar SA, Rusli N, Nasir NH, et al. Find the Missing Millions:

446 Malaysia's experience with nationwide hepatitis C screening campaign in the general population. J Viral

447 Hepat. 2020;27(6):638-43.

16. Markby J, Shilton S, Sem X, Chan HK, Said RM, Siva S, et al. Assessing the impact of simplified HCV

449 care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective

450 observational study. BMJ Open. 2021;11(12):e055142.

451 17. Chan H, Hassali MA, R. MS, R. AHM. Treatment Coverage and Drug Expenditure in Hepatitis C

452 Patients From 2013 to 2019: A Journey of Improving Treatment Accessibility in Malaysia Through

453 Government-led Initiatives. Hepat Mon. 2020;20(9):e107372.

454 18. Chan HK, Hassali MA, Md Said R, Omar H, Abd Mutalib NA, De Rozario FW, et al. A Two-Year

455 Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using

456 a Standard Two-Drug Regimen in Malaysia. Hepat Mon. 2021;21(3):e113226.

457 19. Nguyen LT, Nguyen VTT, Le Ai KA, Truong MB, Tran TTM, Jamil MS, et al. Acceptability and

458 Usability of HCV Self-Testing in High Risk Populations in Vietnam. Diagnostics (Basel). 2021;11(2).

459 20. Reipold EI, Farahat A, Elbeeh A, Soliman R, Aza EB, Jamil MS, et al. Usability and acceptability of

self-testing for hepatitis C virus infection among the general population in the Nile Delta region of Egypt.

461 BMC Public Health. 2021;21(1):1188.

462 21. Fajardo E, Watson V, Kumwenda M, Usharidze D, Gogochashvili S, Kakhaberi D, et al. Usability
463 and acceptability of oral-based HCV self-testing among key populations: a mixed-methods evaluation in
464 Tbilisi, Georgia. BMC Infect Dis. 2022;22(1):510.

465 22. Majam M, Fischer A, Ivanova Reipold E, Rhagnath N, Msolomba V, Lalla-Edward ST. A Lay-User
466 Assessment of Hepatitis C Virus Self-Testing Device Usability and Interpretation in Johannesburg, South
467 Africa. Diagnostics (Basel). 2021;11(3).

468 23. Martinez-Perez GZ, Nikitin DS, Bessonova A, Fajardo E, Bessonov S, Shilton S. Values and
469 preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan. BMC Infect Dis.
470 2021;21(1):609.

471 24. Serumondo J, Shilton S, Nshimiyimana L, Karame P, Dushimiyimana D, Fajardo E, et al. Values and
472 preferences for hepatitis C self-testing among the general population and healthcare workers in Rwanda.

473 BMC Infect Dis. 2021;21(1):1064.

474 25. Gwet KL. Computing inter-rater reliability and its variance in the presence of high agreement. Br
475 J Math Stat Psychol. 2008;61(1): 29-48.

476 26. Ho SY, Su LH, Sun HY, Huang YS, Chuang YC, Huang MH, et al. Trends of recent hepatitis C virus
477 infection among HIV-positive men who have sex with men in Taiwan, 2011-2018. EClinicalMedicine.
478 2020;24:100441.

479 27. Lockart I, Matthews GV, Danta M. Sexually transmitted hepatitis C infection: the evolving
480 epidemic in HIV-positive and HIV-negative MSM. Curr Opin Infect Dis. 2019;32(1):31-7.

481 28. Muhamad NA, Ab.Ghani RM, Abdul Mutalip MH, Muhammad EN. Seroprevalence of hepatitis B
482 virus and hepatitis C virus infection among Malaysian population. Sci Rep. 2020;10(21009).

483 29. Hassan MRA, Chan HK. Comment on: "Projections of the Healthcare Costs and Disease Burden
484 due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018-2040". Appl Health Econ
485 Health Policy. 2020;18(1):139-40.

30. Sun J, Cheng H, Hassan MRA, Chan HK, Piedagnel JM. What China can learn from Malaysia to
achieve the goal of "eliminate hepatitis C as a public health threat" by 2030 - a narrative review. Lancet
Reg Health West Pac. 2021;16:100261.

489 31. Catania JA, Huun C, Dolcini MM, Urban AJ, Fleury N, Ndyetabula C, et al. Overcoming cultural
490 barriers to implementing oral HIV self-testing with high fidelity among Tanzanian youth. Transl Behav
491 Med. 2021;11(1):87-95.

Wei C, Yan L, Li J, Su X, Lippman S, Yan H. Which user errors matter during HIV self-testing? A
qualitative participant observation study of men who have sex with men (MSM) in China. BMC Public
Health. 2018;18(1):1108.

495 33. Figueroa C, Johnson C, Ford N, Sands A, Dalal S, Meurant R, et al. Reliability of HIV rapid diagnostic
496 tests for self-testing compared with testing by health-care workers: a systematic review and meta497 analysis. Lancet HIV. 2018;5(6):e277-e90.

Blas MM, Alva IE, Carcamo CP, Cabello R, Goodreau SM, Kimball AM, et al. Effect of an online
video-based intervention to increase HIV testing in men who have sex with men in Peru. PLoS One.
2010;5(5):e10448.

35. Hawk ME, Chung A, Creasy SL, Egan JE. A Scoping Review of Patient Preferences for HIV SelfTesting Services in the United States: Implications for Harm Reduction. Patient Prefer Adherence.
2020;14:2365-75.

504 36. Merchant RC, Clark MA, Liu T, Rosenberger JG, Romanoff J, Bauermeister J, et al. Preferences for 505 oral fluid rapid HIV self-testing among social media-using young black, Hispanic, and white men-who-506 have-sex-with-men (YMSM): implications for future interventions. Public Health. 2017;145:7-19.

507 37. Gibson BA, Brown SE, Rutledge R, Wickersham JA, Kamarulzaman A, Altice FL. Gender identity, 508 healthcare access, and risk reduction among Malaysia's mak nyah community. Glob Public Health. 509 2016;11(7-8):1010-25.

38. Wait S, Kell E, Hamid S, Muljono DH, Sollano J, Mohamed R, et al. Hepatitis B and hepatitis C in
southeast and southern Asia: challenges for governments. Lancet Gastroenterol Hepatol. 2016;1(3):24855.

513	39. Shilton S, Sem X, Chan HK, Chung HY, Karunanithy A, Markby J, et al. A quasi-randomised
514	controlled trial of online distribution of home-based hepatitis C self-testing for key populations in
515	Malaysia: a study protocol. Trials 23, 304 (2022).

516

517

518 Supporting information

519 S1 Fig. **Contrived results for both the oral fluid- and blood-based tests.** ¹Positive (with clear 520 control and test lines); ²Weak positive (with a clear control line and a faint test line); ³Negative 521 (with only a clear control line); ⁴Invalid (without either control or test lines); ⁵Invalid (with only a 522 clear test line)

Figure 1: Flowchart of participant enrolment.



GP, general population; HCVST, hepatitis C self-testing; MSM, men who have sex with men.

